GlassScriptPhysician profile
Daniel L Shinners
NPI 1205877552
$14,821.88
in general payments reported to CMS, 2019-2025
52 companies · $2,501 in 2025
The $2,501 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,083 · 2020: $830 · 2021: $2,176 · 2022: $2,191 · 2023: $2,772 · 2024: $2,270 · 2025: $2,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,463 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,462.53 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,187.76 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,168.32 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $1,102.82 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,005.29 | 2019-2023 | Stiolto Respimat, Ofev |
| Grifols USA, LLC | $845.04 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $684.85 | 2020-2025 | Glassia |
| Jazz Pharmaceuticals INC. | $639.53 | 2019-2025 | |
| Mylan Specialty L.P. | $536.57 | 2019-2024 | Yupelri |
| Genzyme Corporation | $380.76 | 2019-2025 | |
| Insmed, INC. | $286.83 | 2019-2025 | Arikayce, Brinsupri |
| Breathe Technologies, INC. | $280.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $278.57 | 2019-2024 | |
| Amgen INC. | $271.66 | 2021-2025 | Tezspire, Tavneos |
| Baxter Healthcare | $265.78 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $223.31 | 2020-2024 | Tyvaso |
Show all 51 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shinners listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.